7.4(top 1%)
Impact Factor
7.8(top 1%)
extended IF
127(top 2%)
H-Index
4K
authors
6K
papers
152.3K
citations
5.2K
citing journals
58.1K
citing authors

Most Cited Articles of Cancer Immunology, Immunotherapy

TitleYearCitations
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy2009949
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients2007944
An immune-active tumor microenvironment favors clinical response to ipilimumab2012562
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy2005490
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-132011446
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy2005422
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity2010421
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies1993414
A listing of human tumor antigens recognized by T cells: March 2004 update2005378
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment2009377
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab2014367
A listing of human tumor antigens recognized by T cells2001366
Apoptosis pathways in cancer and cancer therapy2004363
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers2007345
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells2000333
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion2007332
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer2014328
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells2009309
Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes2006300
Role of immature myeloid cells in mechanisms of immune evasion in cancer2006294
Derangement of immune responses by myeloid suppressor cells2004294
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer2009292
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology2012266
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma2013265
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies2007265